A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

ClinicalTrials.gov ID: NCT07808697

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07808697. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.

Study identification

NCT ID: NCT07808697
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: ModernaTX, Inc.; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

SARS-CoV-2

Interventions

mRNA-1283 Biological
mRNA-1273 Biological

Biological

Eligibility (public fields only)

Age range: 6 Months to 11 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 4, 2026 (Actual)
Primary completion: Aug 30, 2029 (Estimated)
Completion: Aug 30, 2029 (Estimated)
Last update posted: Nov 9, 2026

2026 – 2029

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
Orange County Research Center	Ontario	California	91762	Recruiting
Hope Research Network	Miami	Florida	33166	Recruiting
Spotlight Research Center - Internal Medicine	Miami	Florida	33167	Recruiting
Indago Research and Health Cen	Miami Lakes	Florida	33016	Recruiting
MplusM - D&H Tamarac Research Center	Tamarac	Florida	33321	Recruiting
Eagle Clinical Research, LLC	Chicago	Illinois	60621	Not yet recruiting
Great Lakes Research Institute -Southfield	Southfield	Michigan	48075	Recruiting
Senders Pediatrics	South Euclid	Ohio	44121	Not yet recruiting
REX Clinical Trials	Beaumont	Texas	77701	Recruiting
PanAmerican Clinical Research, LLC.	Brownsville	Texas	78520	Recruiting
South Ogden Family Medicine	South Ogden	Utah	84403	Recruiting
Clinical Research Partners	Richmond	Virginia	23226	Recruiting
Childrens Hospital Regional Medical Center	Seattle	Washington	98105	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07808697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 9, 2026 · Synced Nov 13, 2026